MAF1 Antibody

What is MAF1 and why is it important to study?

MAF1 is a highly conserved protein that functions primarily as a repressor of RNA polymerase III-dependent transcription, which is responsible for synthesizing small RNAs including tRNAs and 5S rRNA. MAF1 mediates this repression by interacting with BRF1, a subunit of initiation factor TFIIIB, preventing recruitment of Pol III to promoters . Beyond this canonical role, MAF1 has emerged as a regulatory factor in diverse cellular processes including neural repair after stroke , cell cycle regulation through CDKN1A , and inflammatory responses . The protein consists of 256 amino acids and is predominantly localized in the nucleus . Its study is valuable because MAF1 dysregulation may contribute to various pathological conditions, making it a potential therapeutic target.

What techniques can MAF1 antibody be used for in research settings?

MAF1 antibodies are versatile tools applicable across multiple research techniques:

• Western blotting (WB): Detects MAF1 protein expression levels and phosphorylation states

• Immunoprecipitation (IP): Isolates MAF1 and its interacting partners

• Immunofluorescence (IF): Visualizes subcellular localization of MAF1

• ELISA: Quantifies MAF1 in samples

• Chromatin immunoprecipitation (ChIP): Identifies MAF1 binding to chromatin

For optimal results in each technique, researchers should validate antibody specificity using appropriate positive controls (such as recombinant MAF1 protein) and negative controls (such as MAF1 knockdown samples).

How can I detect different phosphorylation states of MAF1?

MAF1 exists in multiple phosphorylation states that affect its function, with phosphorylation generally inhibiting its repressive activity. To detect these states:

• Use Phos-tag SDS-PAGE gels, which can separate phosphorylated forms of MAF1 based on their mobility shifts

• Follow with immunoblotting using MAF1 antibody

• Compare samples from cells under different conditions (e.g., serum-starved vs. growing cells)

• Include positive controls such as cells treated with mTOR inhibitors (rapamycin or Torin1), which induce MAF1 dephosphorylation

This approach enables visualization of MAF1 as a series of slowly migrating bands representing different phosphorylation states, with dephosphorylated forms migrating faster.

What are the recommended fixation and permeabilization methods for MAF1 immunofluorescence?

For optimal MAF1 detection by immunofluorescence:

• Plate cells onto coverslips and allow overnight attachment

• Rinse cells twice with cold PBS

• Fix with 4% paraformaldehyde for 30 minutes

• Permeabilize with 0.2% Triton X-100

• Incubate with MAF1 primary antibody at room temperature for 2 hours

• Visualize using appropriate fluorophore-conjugated secondary antibodies (AF-594 or AF488)

• Counterstain nuclei with DAPI

This protocol has been validated for detecting nuclear localization of MAF1 in various cell types and enables co-localization studies with other proteins like p65 and NLRP3.

How can MAF1 antibody be used to investigate the relationship between MAF1 and mTOR signaling?

To explore MAF1-mTOR interactions:

• Phosphorylation analysis: Treat cells with mTOR inhibitors (rapamycin or Torin1) and analyze MAF1 phosphorylation status using Phos-tag SDS-PAGE followed by western blotting with MAF1 antibody

• Co-immunoprecipitation: Perform IP with MAF1 antibody to detect interactions with mTOR pathway components under different conditions

• Functional assays: Combine MAF1 knockdown or overexpression with mTOR pathway manipulation and measure:

  • tRNA precursor levels by qRT-PCR

  • Cell cycle progression by flow cytometry

  • Pol III occupancy at target genes by ChIP-qPCR

Research has established that MAF1 is directly phosphorylated by mTORC1, and this phosphorylation regulates MAF1's repressive activity on Pol III transcription. In actively growing cells, MAF1 is phosphorylated and inactive, while mTOR inhibition leads to rapid MAF1 dephosphorylation and subsequent repression of specific Pol III genes .

How can MAF1 antibody be used to study MAF1's role in neural repair and neuroinflammation?

MAF1 has emerged as an intrinsic suppressor of neural repair after ischemic stroke and plays a role in regulating neuroinflammation. To investigate these functions:

• Neural repair studies:

  • Perform immunohistochemistry on brain sections after stroke to assess MAF1 expression and localization in peri-infarct regions

  • Use MAF1 antibody for western blot analysis to quantify changes in MAF1 expression after stroke

  • Combine with markers of neural plasticity to correlate MAF1 levels with repair mechanisms

• Neuroinflammation assessment:

  • Use MAF1 antibody in co-immunoprecipitation experiments to detect interactions with NF-κB/p65

  • Perform ChIP assays to analyze MAF1 binding to the NLRP3 inflammasome gene promoter

  • Combine with ELISA measurement of inflammatory cytokines (IL-1β, IL-18) in cell or tissue lysates

Research has shown that MAF1 significantly suppresses LPS-induced brain inflammatory responses by competing with p65 for binding to the NLRP3 gene promoter, making it a potential therapeutic target for sepsis-associated encephalopathy and other neuroinflammatory conditions .

What are the optimal protocols for using MAF1 antibody in chromatin immunoprecipitation (ChIP) experiments?

For successful MAF1 ChIP experiments:

• Crosslinking and chromatin preparation:

  • Fix cells with 1% formaldehyde for 10 minutes at room temperature

  • Quench with 0.125M glycine

  • Isolate nuclei and sonicate chromatin to generate 200-500bp fragments

• Immunoprecipitation:

  • Pre-clear chromatin with protein A/G beads

  • Incubate overnight with MAF1 antibody (2-5μg per reaction)

  • Include appropriate controls: IgG negative control and positive control (RNA Pol III subunit)

  • Capture antibody-bound chromatin with protein A/G beads

• Analysis:

  • Purify DNA and analyze by qPCR targeting:

    • Pol III-transcribed genes (tRNA genes, 5S rRNA)

    • SINEs in promoters of specific Pol II genes (CDKN1A, GDF15)

    • Control regions (GAPDH promoter)

Research has demonstrated that MAF1 not only binds to Pol III-transcribed genes but also to promoter-associated SINEs within the regulatory regions of specific Pol II genes like CDKN1A, revealing a novel regulatory mechanism .

How can I validate the specificity of a MAF1 antibody?

To ensure MAF1 antibody specificity:

• Positive controls:

  • Use recombinant MAF1 protein

  • Overexpress MAF1 in cell lines with low endogenous expression

• Negative controls:

  • Include MAF1 knockdown samples (siRNA or shRNA-treated cells)

  • Use cells from MAF1 knockout animal models when available

• Size verification:

  • Confirm the detected band is at the expected molecular weight (~28 kDa for human MAF1)

  • Note that phosphorylated forms may show mobility shifts

• Cross-reactivity testing:

  • Test the antibody across species if working with non-human samples

  • Perform peptide competition assays to confirm binding specificity

• Multiple detection methods:

  • Verify results using different techniques (WB, IF, IP)

  • If possible, use antibodies targeting different epitopes

Why might I observe multiple bands when using MAF1 antibody in western blotting?

Multiple bands in MAF1 western blots may reflect:

• Phosphorylation states: MAF1 exists in multiple phosphorylation states that appear as bands with different mobilities. These can be confirmed by:

  • Treatment with phosphatases

  • Comparison with samples treated with mTOR inhibitors

  • Use of Phos-tag gels to enhance separation

• Isoforms or degradation products:

  • Verify whether predicted isoforms exist for your species

  • Include protease inhibitors during sample preparation

  • Compare fresh vs. stored samples

• Non-specific binding:

  • Optimize blocking conditions (try different blocking agents)

  • Increase washing stringency

  • Titrate antibody concentration

If studying phosphorylation is your goal, these multiple bands provide valuable information about MAF1's regulatory state in different conditions.

What are the best controls for MAF1 knockdown or overexpression experiments?

For robust MAF1 manipulation experiments:

For knockdown studies:

• Include multiple siRNA/shRNA targeting different regions of MAF1 mRNA

• Use non-targeting siRNA/shRNA as negative control

• Validate knockdown efficiency by both:

  • qRT-PCR for mRNA levels

  • Western blot for protein levels

• Include functional validation by measuring known MAF1-regulated genes:

  • pretRNA Tyr and pretRNA Leu transcripts should increase with MAF1 knockdown

For overexpression studies:

• Use empty vector controls processed identically

• Include wild-type and phosphorylation-deficient MAF1 variants to distinguish function

• Validate expression by western blot

• Confirm functional effects through:

  • Decreased Pol III transcription

  • Suppressed neurite outgrowth in neuronal models

How does MAF1 function differ between cell types and how can antibodies help investigate this?

MAF1 exhibits context-specific functions that can be investigated using MAF1 antibodies:

• In neurons:

  • MAF1 expression increases in peri-infarct cortex after stroke

  • Nuclear accumulation correlates with suppression of neural repair

  • MAF1 knockdown enhances neural plasticity and functional recovery

• In immune cells:

  • MAF1 suppresses inflammatory responses by competing with p65

  • Regulates NLRP3 inflammasome activation

  • MAF1 overexpression protects against LPS-induced inflammation

• In proliferating cells:

  • MAF1 regulates cell cycle progression through CDKN1A repression

  • MAF1 knockdown arrests cells at G1 phase

To investigate these differences:

• Perform immunofluorescence with MAF1 antibody to compare subcellular localization

• Use western blotting to quantify expression levels and phosphorylation states

• Conduct ChIP-seq to map genome-wide binding patterns across cell types

What is the relationship between MAF1 and p53 pathway, and how can it be studied using MAF1 antibody?

Although the search results don't directly address MAF1-p53 interactions, they suggest potential connections through CDKN1A (p21), which is a key p53 target. To investigate this relationship:

• Co-immunoprecipitation:

  • Use MAF1 antibody to pull down MAF1 complexes

  • Probe for p53 and other pathway components

  • Perform reciprocal IP with p53 antibody

• ChIP sequential analysis (ChIP-seq):

  • Perform ChIP-seq with both MAF1 and p53 antibodies

  • Identify overlap in binding regions

  • Focus on CDKN1A and other cell cycle regulators

• Expression correlation:

  • Compare MAF1 and p53 target gene expression under various conditions

  • Combine with MAF1 knockdown/overexpression

• Functional assays in p53-null vs. wild-type cells:

  • Assess MAF1 binding to CDKN1A promoter in both backgrounds

  • Measure effects of MAF1 manipulation on cell cycle in p53+/+ vs p53-/- cells

Research has shown that MAF1 knockdown upregulates CDKN1A expression approximately 10-fold and arrests cells at G1 phase, suggesting MAF1 may intersect with p53-regulated cell cycle control pathways .

How can recombinant MAF1 protein be used alongside MAF1 antibody to enhance experimental validity?

Recombinant MAF1 protein serves multiple purposes in MAF1 antibody-based research:

• As a positive control:

  • Include purified recombinant MAF1 in western blots to confirm antibody specificity

  • Use as a standard for quantification in ELISA

• For antibody validation:

  • Pre-incubate antibody with recombinant protein for blocking experiments

  • Test antibody recognition across species using recombinant proteins from different organisms

• In binding assays:

  • Use purified MAF1 in DNA binding assays to confirm direct interaction with target sequences

  • Study protein-protein interactions in cell-free systems

• For structure-function studies:

  • Generate wild-type and mutant MAF1 recombinant proteins

  • Compare antibody recognition of different domains/modifications

Recombinant MAF1 expression has been successfully established in prokaryotic systems using vectors like pET-28a(+), yielding functional protein with antifungal activity (in the case of Musca domestica MAF-1) .

How can MAF1 antibodies be used to investigate MAF1's potential as a therapeutic target?

MAF1 has emerged as a potential therapeutic target in several contexts:

• For neural repair after stroke:

  • MAF1 inhibition enhances neural plasticity and functional recovery

  • MAF1 antibodies can monitor changes in MAF1 expression/activation during experimental therapies

  • Immunohistochemistry can assess MAF1 nuclear localization in response to potential inhibitors

• For inflammatory conditions:

  • MAF1 regulation might be therapeutic for sepsis-associated encephalopathy

  • MAF1 antibodies can monitor MAF1-NF-κB/p65 interactions

  • Immunoblotting can assess effects of therapies on MAF1-regulated inflammatory pathways

• For validating MAF1-targeting compounds:

  • Use MAF1 antibodies to:

    • Confirm target engagement in cellular models

    • Track changes in MAF1 phosphorylation state

    • Assess downstream effects on MAF1-regulated genes

Research demonstrates that Maf1 knockdown in peri-infarct cortex significantly enhances neural plasticity and functional recovery after stroke, suggesting MAF1 inhibition could be a promising therapeutic approach .

What are the best practices for using MAF1 antibodies in tissue microarrays or in situ analyses?

For tissue-based MAF1 detection:

• Tissue preparation:

  • For frozen sections: Fix in cold acetone or 4% paraformaldehyde

  • For FFPE sections: Optimize antigen retrieval (citrate buffer, pH 6.0, or EDTA buffer, pH 9.0)

• Staining protocol optimization:

  • Test antibody dilutions (typically 1:100-1:500)

  • Extend primary antibody incubation (overnight at 4°C)

  • Include positive control tissues (brain cortex, liver)

  • Use detection systems with signal amplification for low-abundance expression

• Validation approaches:

  • Perform parallel western blot analysis of tissue lysates

  • Include tissues from MAF1 knockdown/knockout models

  • Compare nuclear vs. cytoplasmic staining patterns in different physiological states

• Analysis considerations:

  • Quantify nuclear vs. cytoplasmic MAF1 localization

  • Correlate with markers of cell state (proliferation, stress, inflammation)

  • Consider dual staining with cell-type specific markers

Research has shown that MAF1 nuclear accumulation increases in neurons of peri-infarct cortex after stroke, correlating with suppressed neural plasticity .